Kiteplatin: Differential binding between GSH and GMP

Glutathione (GSH) plays an important role in the development of resistance to platinum-based chemotherapy, since it can prevent drug binding to DNA and resulting apoptosis of tumor cells. The recently re-discovered drug candidate kiteplatin was found active toward cisplatin- and oxaliplatin-resistant tumor cells, and this could be related to a different interplay of drug-inactivation/DNA-interaction processes. In this study GSH and GMP have been chosen as simple models of platinophiles and DNA, respectively, and the reactivity of kiteplatin has been tested toward GMP, after previous interaction with GSH; toward GSH, after previous interaction with GMP; and toward GMP and GSH simultaneously.